Bone News and Research

RSS

Gene causing periodontitis, rheumatoid arthritis and osteoporosis identified

Investigators at Hospital for Special Surgery, collaborating with researchers from other institutions, have contributed to the discovery that a gene called interferon regulator factor-8 (IRF-8) is involved in the development of diseases such as periodontitis (gum disease), rheumatoid arthritis and osteoporosis. The study, which will be published online August 30, ahead of print, in the journal Nature Medicine, could lead to new treatments in the future.

2 Sep 2009

CT screening for coronary artery calcification can cause radiation-induced cancer

A study based on computer modeling of radiation risk suggests that widespread screening for the buildup of calcium in the arteries using computed tomography scans would lead to an estimated 42 additional radiation-induced cancer cases per 100,000 men and 62 cases per 100,000 women, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

$Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed$

Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed

This week TCA Cellular Therapy`s Medical Director Gabriel Lasala, M.D. presents advances in adult stem cell treatments for severe limb ischemia and refractory coronary ischemia at the European Society of Cardiology Congress in Barcelona, Spain.

2 Sep 2009

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

2 Sep 2009

Misonix commences direct to hospital sales of its SonaStar Ultrasonic Surgical Aspirator in the US

Misonix, Inc., (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the second expansion of its direct sales channel for the United States, which was first disclosed in June 2008.

2 Sep 2009

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

2 Sep 2009

$Prolonged surgery should be avoided in trauma patients with multiple fractures$

Prolonged surgery should be avoided in trauma patients with multiple fractures

Trauma patients who sustain multiple fractures are often in serious condition when they arrive at the emergency department. A review article published in the September 2009 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) explains that trauma patients who have several orthopaedic injuries and are considered to be in unstable condition should only have a few hours of surgery when first arriving at the hospital. This principle is known as 'damage control'.

2 Sep 2009

New method found for the diagnosis of cartilage disease

In its quest to find new strategies to treat osteoarthritis and other diseases, a Boston University-led research team has reported finding a new computer tomography contrast agent for visualizing the special distributions of glycosaminoglycans (GAGs) - the anionic sugars that account for the strength of joint cartilage.

2 Sep 2009

Ground breaking surgery leaves no unsightly scar

Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.

2 Sep 2009

Daytime surgeries reduce minor complication rates

Patients who have after-hour orthopaedic surgeries risk a slightly higher rate of necessary follow-up surgeries, according to a study published in the September 2009 issue of The Journal of Bone and Joint Surgery (JBJS). The data also suggests that patients whose surgeries took place during the day have the same healing, recovery time, and major complication rates as patients who have surgery after hours.

2 Sep 2009

Circulating endothelial cells play a fundamental role in the development of cancer in children

Endothelial progenitor cells may play a role in the start and progression of metastatic disease in children with cancer, according to study results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

1 Sep 2009

TriboFit Hip System receives CE Class III Certificate

Active Implants Corporation (AIC) today announced that it has received a CE Class III Certificate for its TriboFit® Hip System.

1 Sep 2009

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir’s existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.

1 Sep 2009

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

1 Sep 2009

New technique developed for the treatment of cancer

A new paradigm in the way we look at cancer with important implications on how we treat it is about to be published in the British Journal of Cancer by Portuguese, Belgian and American researchers.

1 Sep 2009

Study provides insights into genes that help maintain youthfulness of the skin

In the new print issue of Nature Genetics, scientists in Singapore and Germany report that mutations in the PYCR1 gene cause the rare genetic condition that results in premature skin aging and that is known as "wrinkly skin syndrome."

1 Sep 2009

Mitoxantrone is highly efficient in suppressing multiple sclerosis

According to data supplied by the German Multiple Sclerosis Society's national MS register (DMSG - Deutsche Multiple Sklerose Gesellschaft), up to 10% of German MS patients have been treated with mitoxantrone in the past few years.

1 Sep 2009

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading manufacturing contractor, in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product.

31 Aug 2009

HOYA Conbio to feature premium dental lasers at LVI Global's first branch in Brisbane

HOYA ConBio, a global leader in dental and aesthetic lasers, today announced an agreement with The Las Vegas Institute for Advanced Dental Studies (LVI) Global, an internationally renowned provider of post-graduate dental education, to feature premium dental lasers at LVI Global's first branch in Brisbane, Australia. Effective November 1, this new partnership builds on HOYA ConBio's long-standing involvement at LVI Global's headquarters in Las Vegas.

31 Aug 2009

Bone News and Research

Gene causing periodontitis, rheumatoid arthritis and osteoporosis identified

CT screening for coronary artery calcification can cause radiation-induced cancer

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed

New findings on molecular imaging and prostate cancer

Misonix commences direct to hospital sales of its SonaStar Ultrasonic Surgical Aspirator in the US

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Prolonged surgery should be avoided in trauma patients with multiple fractures

New method found for the diagnosis of cartilage disease

Ground breaking surgery leaves no unsightly scar

Daytime surgeries reduce minor complication rates

Circulating endothelial cells play a fundamental role in the development of cancer in children

TriboFit Hip System receives CE Class III Certificate

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

New technique developed for the treatment of cancer

Study provides insights into genes that help maintain youthfulness of the skin

Mitoxantrone is highly efficient in suppressing multiple sclerosis

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

HOYA Conbio to feature premium dental lasers at LVI Global's first branch in Brisbane

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News